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Abstract 
Background: Inflammatory bowel disease (IBD), is a debilitating group of chronic diseases including Crohn’s Disease 
(CD) and ulcerative colitis (UC), which causes inflammation of the gut and affects millions of people worldwide. At 
different taxonomic levels, the structure of the gut microbiota is significantly altered in IBD patients compared to that 
of healthy individuals. However, it is unclear how these IBD-affected bacterial groups are related to other common 
bacteria in the gut, and how they are connected across different disease conditions at the global scale.
Results: In this study, using faecal samples from patients with IBD, we show through diversity analysis of the micro-
bial community structure based on the 16S rRNA gene that the gut microbiome of IBD patients is less diverse com-
pared to healthy individuals. Furthermore, we have identified which bacterial groups change in abundance in both 
CD and UC compared to healthy controls. A substantial imbalance was observed across four major bacterial phyla 
including Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria, which together constitute > 98% of the gut 
microbiota. Next, we reconstructed a bacterial family co-abundance network based on the correlation of abundance 
profiles obtained from the public gut microbiome data of > 22,000 samples of faecal and gut biopsies taken from 
both diseased and healthy individuals. The data was compiled using the EBI metagenomics database (Mitchell et al. in 
Nucleic Acids Res 46:D726–D735, 2018). By mapping IBD-altered bacterial families to the network, we show that the 
bacterial families which exhibit an increased abundance in IBD conditions are not well connected to other groups, 
implying that these families generally do not coexist together with common gut organisms. Whereas, the bacterial 
families whose abundance is reduced or did not change in IBD conditions compared to healthy conditions are very 
well connected to other bacterial groups, suggesting they are highly important groups of bacteria in the gut that can 
coexist with other bacteria across a range of conditions.
Conclusions: IBD patients exhibited a less diverse gut microbiome compared to healthy individuals. Bacterial groups 
which changed in IBD patients were found to be groups which do not co-exist well with common commensal gut 
bacteria, whereas bacterial groups which did not change in patients with IBD were found to commonly co-exist with 
commensal gut microbiota. This gives a potential insight into the dynamics of the gut microbiota in patients with IBD.
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Introduction
Inflammatory bowel disease (IBD), a group of chronic 
intestinal disorders including Crohn’s disease (CD) and 
ulcerative colitis (UC), causes inflammation of the gut 
and affects millions of people worldwide [1–4]. Both CD 
and UC diseases are differentiated by their location and 
levels of inflammation in the gastrointestinal (GI) tract. 
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UC mostly involves inflammation to the rectum and 
colon, whereas CD most often affects the terminal ileum 
and colon though in some cases it can affect any part of 
the GI tract [2, 5]. Currently, there is no full cure for IBD, 
but different treatments such as taking steroids, immu-
nosuppressants, liquid diet or surgery can help in reduc-
ing the symptoms [5]. To date, the exact cause of IBD is 
not understood, however, a combination of genetic vari-
ants, environmental factors, deregulated host immune 
system, and gut microbiota dysbiosis is associated with 
IBD [6–16].
More than 215 IBD-associated loci have been identi-
fied so far from various genome-wide association studies 
(GWAS) [7]. It has been reported that a large percent-
age (~ 30%) of these loci are common between CD and 
UC, showing involvement of common biological pro-
cesses in both conditions [14, 17]. Moreover, these IBD-
associated loci are mostly involved with immune system 
deregulation, a process which the gut microbiome has 
also been implicated in [18]. The gut microbiota, which 
has a complex community of a hundred trillion bacte-
rial and archaeal cells comprising more than a thousand 
species, provides benefits to the host such as short-chain 
fatty acids (SCFA) and amino acids, metabolism of undi-
gested carbohydrate, and stimulation of the immune 
system [19, 20]. In patients with IBD, the structure and 
the composition of the gut microbiota is severely altered 
compared to that of a healthy condition [10, 13, 18, 21]. 
Previous work has reported imbalances in IBD patients 
for the Firmicutes and Bacteroidetes at the phylum level, 
and Ruminococcaceae, Veillonellaceae, Christensenel-
laceae, Bacteroidaceae, and Rikenellaceae at the family 
level. However, there is a large degree of variability across 
studies, with many reporting contradictory findings. In 
particular, it is unclear what the relationship is between 
microbial groups when there is inflammation of the gut 
epithelium during various diseased states. There is fur-
thermore, a general knowledge gap in establishing the 
relationships between microbial groups across different 
disease conditions.
The aim of the current work was to investigate the rela-
tionships between changing microbial groups in IBD. 
In particular, we wanted to understand which microbial 
groups differ during IBD, and how these groups differ 
in co-abundance patterns across a variety of diseases at 
the global scale. To do this, we initially investigated the 
gut microbial imbalance, at different taxonomic lev-
els for healthy volunteers and CD and UC patients. We 
next reconstructed a network of the co-abundance pat-
terns of different bacterial groups using publicly avail-
able data from a variety of studies at a global scale. Our 
results indicate that the bacterial groups which increase 
in abundance during IBD are specific to both CD and UC 
conditions. In comparison, bacterial groups which did 
not change in abundance during different disease states 
are well connected in global networks, giving us a bet-
ter understanding of the dynamics of the microbiome in 
both health and disease.
Results and discussion
Gut microbial richness in IBD patients
We collected faecal samples from 30 individuals (9 CD 
patients, 11 UC patients and 10 healthy volunteers) and 
performed 16S rRNA taxonomic profiling to under-
stand changes in community structure during disease 
with resulting data analysed using the DADA2 pipeline. 
Amplicon sequence variants (ASVs) were used as a meas-
ure of diversity. As previously reported, species richness 
in the gut of IBD patients (both CD and UC) was lower 
than that of healthy volunteers [10, 13]. Moreover, within 
the IBD patients groups, the gut of CD patients exhibit 
substantially lower species richness than that of UC 
patients (Fig.  1a). As a measure of diversity, we identi-
fied a total of 2261 ASVs, of which 81% belong to the Fir-
micutes, 9.25% Bacteroidetes, 5.13% Proteobacteria, and 
3.14% ASVs are from Actinobacteria. Combined, these 
four phyla constitute more than 98% of the total identified 
ASVs [22, 23]. To understand how this compared to other 
studies, we investigated the global microbial species-
richness in the human gut across > 22,000 samples from 
113 different studies from a variety of conditions (EBI 
metagenomics accession numbers [1] in Additional file 1: 
Table S1). We have considered only the known species in 
each study and made a unique list of gut bacterial spe-
cies across studies. Similar to our experimental observa-
tions, the four phyla including Firmicutes, Bacteroidetes, 
Proteobacteria and Actinobacteria comprised > 94% of 
the total diversity in the gut, with the Firmicutes being 
the most species-rich phylum across conditions (Fig. 1b). 
However, the number of species identified as belonging 
to the Firmicute Phyla in our dataset (81% of all identi-
fied species from 20 IBD and 10 healthy condition sam-
ples) is substantially higher than what is usually reported 
at a global level (38.18%). As the observation comes from 
2/3 of IBD patient and 1/3 of healthy control samples, 
this increased level of Firmicutes species-richness was 
attributed to the high number of IBD samples. Analysis 
of global studies for species-richness of Proteobacteria 
demonstrated this phyla usually accounts for 31.18% of 
all species, however this was substantially lower in our 
dataset (5.13%). Finally, the richness of Bacteroidetes was 
also reduced in our dataset compared to the global data-
sets (9.24% in our study compared to 14.35% globally). 
We find a similar observation when considering all OTUs 
from individual EBI gut microbiome studies (Additional 
file 2: Figure S1).
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After identifying the differences at different taxo-
nomic levels for each disease condition, for future work 
it is crucial to understand the reasons for such dysbiosis 
and whether they are causative or consequential of dis-
ease. Studies suggest that metabolic dependency [24] and 
nutritional preferences [25] between microorganisms are 
driving forces in microbial community formation. For 
example, metabolic cooperation between bacteria is cru-
cial to microbial assemblages and changes to this could 
cause shifts across the whole community. For future 
work, it would be interesting to investigate the microbial 
metabolic interactions during disease and how this com-
pares to a healthy gut.
The gut microbial abundance at different taxonomic levels 
in IBD patients
Compared to the healthy controls, both IBD patient 
groups (CD and UC patients) demonstrated strong 
microbial imbalance at different taxonomic levels (Fig. 2). 
At the phylum level, both IBD conditions exhibit an 
increased abundance of Firmicutes and Actinobacteria, 
relative to the controls. In particular, the abundance of 
this phyla during UC, was far greater than CD or healthy 
controls. For the two other dominant bacterial phyla, the 
Proteobacteria and Bacteroidetes, the abundance pro-
files varied across disease conditions (Fig.  2a). In CD, 
the abundance of Bacteroidetes, which is often associ-
ated with a healthy gut, was deceased 2.4-fold, whereas 
the abundance of Proteobacteria, a phyla associated 
including wide variety of pathogens, was increased 3.8 
fold. Interestingly, for patients with UC the abundance of 
Proteobacteria was decreased (3.4 fold) relative to con-
trols and there was no significant differences in levels 
Bacteroidetes [26]. Several studies have reported the gut 
microbial imbalances for IBD, however, the imbalance at 
the level of different phylum is variable across studies [10, 
13, 18, 21, 27, 28]. This could likely be a reflection on the 
lack of standardisation across microbiome techniques, or 
perhaps due to a heterogeneity in the microbiome associ-
ated with disease.
We further investigated how different taxonomic lev-
els belonging to each of the main four phyla, Firmicutes, 
Proteobacteria, Bacteroidetes, and Actinobacteria, were 
changed during IBD. For Firmicutes, the most abun-
dant phylum in the gut in all conditions, we observed 
four classes and nine different families which changed in 
abundance relative to healthy controls. For CD patients, 
the abundance of two classes including Clostridia and 
Erysipelotrichia, was reduced, and three families includ-
ing Ruminococcaceae, Christensenellaceae and Erysip-
elotrichaceae were reduced relative to healthy controls. 
The level of two other two classes such as Negativicutes 
and Bacilli (obligately aerobic) and five families includ-
ing Veillonellaceae, Lactobacillaceae, Acidaminococ-
caceae, Streptococcaceae and Peptostreptococcaceae 
was increased, similar to the imbalance in their parent 
phylum Firmicutes. Interestingly, Lachnospiraceae, the 
most abundant Firmicutes family, was at a similar level to 
the control. For UC patients, the abundance of the Fir-
micute classes Clostridia, Negativicutes and Bacilli, and 
Fig. 1 Microbial diversity and richness. a Species richness is substantially less in CD patient samples compared to the healthy control and UC 
patient samples. Shannon alpha diversity plot demonstrate that CD patients samples are less diverse compared to the healthy control and UC 
patient samples (inset figure). b Phylum level richness in the gut microbiota from our samples (left side Y-axis shown in green) compared to the 
global gut microbial species richness obtained across more than 20 K samples from a variety of conditions (right side Y-axis shown in black)
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Firmicute families Ruminococcaceae, Lachnospiraceae, 
Veillonellaceae, Streptococcaceae and Peptostreptococ-
caceae were increased. The Erysipelotrichia class and 
Erysipelotrichaceae family were the same as the controls, 
whereas, three families including Acidaminococcaceae, 
Christensenellaceae and Lactobacillaceae, were reduced 
in abundance. For Bacteroidetes, which is the only 
reduced phylum in CD, we observed a reduced abun-
dance in the Bactersoidia class and Bacteroidia families 
Bacteroidaceae and Rikenellaceae. The Prevotellaceae 
family, in particular, was increased in CD patients. For 
UC patients, the only families to change of the Bacteroi-
detes was the Rikenellaceae and Tannerellaceae families 
which were decreased in abundance, and the Prevotel-
laceae which increased in abundance as with CD. Finally, 
for the Proteobacteria phylum, we observed an imbalance 
in Enterobacteriaceae and Burkholderiaceae families, 
with the abundance level of Enterobacteriaceae increased 
in CD patients and decreased in UC patients com-
pared to the controls. Burkholderiaceae abundance was 
increased for both CD and UC patients. Finally, for the 
Actinobacteria phylum, the abundance level of both the 
Fig. 2 The gut microbial abundance. a Phylum, b Class and c Family level abundance in different conditions. Classes and families belonging to the 
four most abundant phylum across conditions are grouped according to phylum
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class Coriobacteriia and family Coriobacteriaceae was 
increased in both IBD conditions relative to the controls, 
whereas the class Actinobacteria and family Bifidobac-
teriaceae was reduced [13, 29]. In summary, we demon-
strate that multiple families of a class, classes of a phyla 
differ between both the IBD conditions, and between 
each IBD condition and healthy control. This suggests 
that changes in one bacterial family has consequences for 
others. To investigate this further, we used co-occurrence 
network analysis to establish patterns of how bacterial 
groups increase and decrease across global studies.
Global co‑abundance in the gut of different bacterial 
families
The gut microbiota abundance profiles from > 22,000 
samples across a variety of conditions from 113 differ-
ent studies was analysed to explore how different bac-
terial groups change across global studies. Using the 
Pearson’s correlation test, we built a network of signifi-
cantly co-abundant (Pearson’s correlation coefficient > 0.3 
and P value < 1e−10) bacterial families across a range of 
conditions collected from global studies (Fig.  3ai). We 
observed that the majority of bacterial families in the 
network belonged to the phyla Proteobacteria, Actino-
bacteria, Firmicutes and Bacteroidetes (Fig.  3aii). In the 
global gut bacterial family–family co-abundance net-
work (Fig. 3ai), family nodes of 45% of the total connec-
tions are from the same phylum, compared to a random 
network of the same size where percentage connections 
were much lower (~ 30%) (Fig.  3aiii). This suggests that 
groups from the same phylum, which likely have similar 
metabolic requirements, are likely to change abundance 
as a collective. To understand the family level microbial 
imbalance during IBD, we further considered a subnet-
work of the global family co-abundance network, where 
at least one family node was from the most abundant 
bacterial families in either CD, UC or healthy subjects. In 
this subnetwork, we highlighted bacterial families which 
were changed during CD or UC, compared to the healthy 
(Fig. 3b, c).
In CD, seven bacterial families including Coriobac-
teriaceae, Prevotellaceae, Burkholderiaceae, Veillonel-
laceae, Streptococcaceae, Pseudomonadaceae and 
Acidaminococcaceae have increased abundance com-
pared to the healthy controls (Fig. 2c), however, only two 
families including Prevotellaceae and Veillonellaceae are 
connected in the global network (Fig. 3b). In contrast, the 
level of five other families including Erysipelotrichaceae, 
Christensenellaceae, Ruminococcaceae, Bacteroidaceae 
and Rikenellaceae, were well connected in the global 
network (Fig.  3b) and had reduced abundance in CD 
(Fig.  2c). Similarly, for UC, families with an increased 
abundance in UC were less well connected on the global 
scale (Fig. 3c). This suggests that bacterial groups which 
increase in abundance during IBD, are not typically asso-
ciated with the healthy gut microbiome, nor do they 
commonly co-exist with commensals observed in the 
healthy gut. Furthermore, families which had increased 
abundance levels in healthy conditions compared to 
CD are very well connected, suggesting microbes in the 
gut of healthy individuals exist as a co-operative micro-
bial assemblage. In particular, the connection between 
families such as Bacteroidaceae and Ruminococcaceae 
in the co-abundance network indicates that they may 
coexist together in across conditions, potentially due to 
similarities in physiology or the presence of metabolically 
cooperating species. For future work, it would be highly 
interesting to examine species of these families and 
investigate the relationships between these organisms.
Conclusions
In summary, our analysis demonstrates that IBD patients 
(both CD and UC) and healthy volunteers have reduced 
species richness, and imbalances in families, classes, 
and phyla, relative to healthy volunteers. Four bacterial 
phyla including Firmicutes, Bacteroidetes, Proteobac-
teria and Actinobacteria comprised > 98% of the species 
in this study. To understand how bacteria assemblages 
depend on co-operation, we reconstructed a large co-
abundance network based on the public gut microbiome 
data of > 22,000 samples. From this we demonstrated that 
the bacterial families which have an increased abundance 
level in IBD conditions are not well connected to other 
bacterial groups in the global family co-abundance net-
work. This suggests that these bacteria do not co-exist 
with healthy gut microbial commensals and supports the 
concept that healthy assemblages are dependent on met-
abolic co-operation, due to the high connectivity of bac-
terial groups found in healthy conditions across > 22,000 
samples.
Methodology
Sample collection and DNA extraction
Samples were collected from patients in standard 300 ml 
sterilin tubes and frozen immediately in −80 °C. Patients 
were asked to produce the first-morning sample for con-
sistency and to avoid alcohol the previous 24 h. Samples 
were thawed and DNA was extracted using FastDNA 
Spin Kit for Soil (MPBiomedicals) [30] as per the manu-
facturer’s instructions.
16S rRNA sequencing
454 pyrosequencing using 16S universal eubacterial 
primers 27F and 534R [31] was performed by Molecu-
lar Research (MRDNA), Shallowater, Texas, using an 
adapted protocol developed in [32]. Number of reads per 
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Fig. 3 The human gut bacteria family co-abundance. a, i The network represents the global human gut bacterial family coexistence considering 
the four most highly abundant gut bacterial phyla. The network connections are based on correlation test (P-value < 1e−10 and Pearson’s 
correlation coefficient > 0.3). Edge connection between families from the same phylum is shown in black lines whereas the family connection 
between different phyla is shown in grey lines. Family nodes are coloured according to phylum. a, ii This graph demonstrates the number of families 
(i.e. nodes) belonging to a different phylum in the global bacterial family coexistence. a, iii The percentage connection between families from the 
same phylum is substantially higher in the global bacterial family coexistence compared to a random network of the same size. b A subnetwork 
of the global human gut bacterial family coexistence network where the abundance level of at least one family node in a connection is > 1.5-fold 
higher in either CD or healthy condition against each other. c Similarly, a subnetwork of the global human gut bacterial family coexistence network 
where the abundance level of at least one family node in a connection is > 1.5 fold higher in either UC or healthy condition against each other. Edge 
connection between families from the same phylum is shown in black lines whereas the family connection between different phylum is shown in 
grey lines. Family belonging to different phyla are shown in different shapes. The node colour shows the increased abundance level in a disease (CD 
or UC) or healthy condition compared to each other. The size of the node represents the abundance level in a healthy condition
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sample ranged from 6936 to 100,972, with an average of 
38,931 reads per sample.
Bioinformatic analysis of 16S rRNA sequencing data
16S rRNA high-throughput sequencing data was ana-
lysed by following the workflow from Callahan et al. [33]. 
Quality checking, filtering and trimming of fastq files 
were performed by functions from the dada2 package in 
R [34]. After filtering the reads, high-resolution Ampli-
con Sequence Variants (ASVs) were inferred using dada 
function [34]. ASVs are a higher-resolution analogue of 
the traditional OTUs. Chimeric sequences were removed 
and taxonomy assigned to ASVs based on the naive 
Bayesian classifier method with silva_nr_v132_train_set.
fa as the training set [34]. Species-richness and alpha 
diversity (Shannon) were analysed by plot_richness func-
tion from the phyloseq package in R [35]. To make the 
rarefaction species richness curve, ‘rarecurve’ function 
from the vegan package [36] in R was used.
Statistical analysis: bacterial family co‑abundance network 
based on microbiome data
Taxonomic assignments, containing a detailed taxonomy 
and abundance data of OTUs or ASVs in samples, of 
113 gut microbiome studies, covering more than 22,000 
samples, were downloaded from the EBI metagenomics 
database [1]. The data were then parsed and tables con-
taining bacterial abundance from different phyla, classes 
and families were generated. Abundance at the level of 
phylum was then used for the global gut microbial abun-
dance. The family-level bacterial abundance was used 
to construct the bacterial family–family coexistence 
network. For each pair of bacterial families, Pearson’s 
correlation test was performed. Family nodes were con-
nected when P-value < 1e−10 and Pearson’s correlation 
coefficient > 0.3.
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